Effect of pharmaceutical intervention on serum Advanced Glycated End products levels in women with Polycystic Ovary Syndrome

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 532-553-Hyperandrogenic Disorders
Basic/Clinical
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-545
Claire Christakou*1, Christina Piperi2, Sarantis Livadas3, Evangelos Marinakis1, Anastasios Kollias3, Ilias Katsikis4, Dimitrios Panidis5 and Evanthia Diamanti-Kandarakis6
1Sotiria Hospital, Athens University Medical School, Greece, 2University of Athens Medical School, Athens, Greece, 3Unit of Endocrinology, Metabolism and Diabetes, Athens, Greece, 4Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece, 5Aristotle Univ Thessaloniki, Thessaloniki, Greece, 6Medical School University of Athens, Athens, Greece
Objective: To investigate whether oral contraceptives(OCPs) and metformin affect serum AGEs levels in PCOS women.

Methods : 109 women with PCOS were randomized to receive oral treatment with an OCP containing ethinyl-estradiol plus cyproterone acetate (OCP 1), with an OCP containing ethinylestradiol plus drospirenone (OCP 2) or with metformin (850 mg twice daily) for 6 months. Serum AGEs levels, hormonal and metabolic parameters as well as C-reactive protein levels were determined at baseline,after three months and after six months of treatment.

Results: The three groups had similar age and BMI at baseline. Serum AGEs levels at baseline were also comparable between the three groups. The mean BMI was increased at 6 months in groups A and B ,but was decreased in group C. Serum AGEs levels were significantly reduced in all groups at 6 months of treatment compared to baseline , but the percent of reduction was significantly greater in group C than in group A and group B. The percent decrease of serum AGEs correlated only with baseline BMI , but was independent of the BMI change,as well as other metabolic,hormonal and inflammatory parameters.

Conclusions: For the first time, metformin is shown to be superior tο OCPs in reducing circulating levels of AGEs. Thus, metformin may be superior to OCPs in alleviating the cardiovascular risk associated with PCOS. This beneficial effect appears to be independent of BMI changes observed in all treatment groups and specifically, the weight reducing effect of metformin.

Nothing to Disclose: CC, CP, SL, EM, AK, IK, DP, ED

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm